Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
A completed study investigating the impact of gut and intratumoral microbiomes on chemo-induced immune responses in patients with triple-neg…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating dual-target CAR-NK cells designed to treat HER2-positive and triple-negative breast cancers, with t…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer [NA]
This clinical trial update describes a study on metabolic flexibility in patients with early triple-negative breast cancer, which is current…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: Leflunomide in Previously Treated Metastatic Triple Negative Cancers [Phase 1, Phase 2]
Clinical trial update shows completion of a Phase 1/2 study evaluating leflunomide in previously treated metastatic triple-negative breast c…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases [Phase 1, Phase 2]
A Phase 1/2 trial evaluating Bintrafusp alfa in combination with Pimasertib for brain metastases has been terminated, with results posted in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) [Phase 3]
Phase 3 TROPION-Breast03 trial evaluating datopotamab deruxtecan (Dato-DXd) with or without durvalumab versus investigator's choice in Stage…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. [Phase 2]
Phase 2 trial by the SOLTI Breast Cancer Research Group to predict sensitivity to Olaparib in patients with unresectable locally advanced or…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer [Phase 2]
Phase 2 study of AK117/AK112 for metastatic and locally advanced triple-negative breast cancer is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID [Phase 1]
Phase 1 clinical trial update of RNA-immunotherapy IVAC_W_bre1_uID and IVAC_M_uID in triple-negative breast cancer, with the study status no…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer [Phase 2]
Phase 2 trial results update evaluating estradiol for ER beta–positive, triple-negative breast cancer in locally advanced or metastatic dise…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer [NA]
The study evaluating circulating tumor DNA–based minimal residual disease detection in early-stage breast cancer is currently suspended.
-
CLINICAL_TRIALS trial_result · 2026-03-03Clinical Trial Update: Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating preoperative chemotherapy with pembrolizumab and low or high dose radiation in node-positive, triple-negat…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy [Phase 2]
A Phase 2 trial evaluating the safety and preliminary effectiveness of BNT327 in combination with chemotherapy for locally advanced, triple-…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: PRO1107 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
The Phase 1/2 PRO1107 trial in advanced solid tumors, including endometrial and ovarian cancers, has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating nab-paclitaxel plus atezolizumab given before surgery in triple-negative breast cancer has completed and posted res…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer [Phase 2]
A Phase 2 trial evaluating ARX788 for HER2-low breast cancer (locally advanced unresectable or metastatic) is currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Onvansertib + Paclitaxel In TNBC [Phase 1, Phase 2]
This document reports an ongoing Phase 1/2 clinical trial evaluating the combination of onvansertib with paclitaxel in patients with triple-…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer [NA]
Feasibility study evaluating a biobehavioral stress reduction intervention for patients with breast cancer, including triple-negative breast…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating NT-I7 (efineptakin alfa) in combination with pembrolizumab in adults with advanced solid tumors has completed and…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies [Phase 1]
Phase 1 dose-escalation and expansion study of PRGN-3007 UltraCAR-T cells in patients with advanced hematologic and solid tumors has complet…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]
Phase 1/2 study of novel anti-cancer agents in patients with metastatic triple-negative breast cancer; results have been posted on 2026-02-0…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments [Phase 2]
A Phase 2 trial evaluating sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who have had at least two…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating sacituzumab govitecan in combination with atropine to improve tolerability in advanced breast cancers, i…
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating docetaxel chemotherapy in combination with pembrolizumab and interleukin-12 gene therapy for triple-nega…
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications [Phase 1]
A Phase 1 clinical trial update describes evaluation of BBI-355 (CHK1 inhibitor) in combination with BBI-825 (RNR inhibitor) for tumors with…